Capital World Investors Has $15.09 Billion Stake in Eli Lilly and Company (NYSE:LLY)

Capital World Investors trimmed its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 3.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 19,552,507 shares of the company's stock after selling 803,439 shares during the period. Eli Lilly and Company makes up about 2.3% of Capital World Investors' holdings, making the stock its 6th largest holding. Capital World Investors owned approximately 2.06% of Eli Lilly and Company worth $15,094,648,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. CWA Asset Management Group LLC increased its stake in shares of Eli Lilly and Company by 11.9% during the fourth quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock worth $5,245,000 after buying an additional 724 shares during the period. Centerpoint Advisory Group acquired a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $514,000. M&T Bank Corp grew its stake in shares of Eli Lilly and Company by 0.7% during the third quarter. M&T Bank Corp now owns 266,822 shares of the company's stock worth $236,389,000 after purchasing an additional 1,867 shares in the last quarter. Kentucky Trust Co purchased a new stake in Eli Lilly and Company during the 4th quarter worth about $834,000. Finally, Proficio Capital Partners LLC raised its position in shares of Eli Lilly and Company by 30.2% during the 4th quarter. Proficio Capital Partners LLC now owns 6,739 shares of the company's stock worth $5,202,000 after acquiring an additional 1,562 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their price objective for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a report on Friday, January 17th. Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research report on Monday, February 3rd. Finally, Wells Fargo & Company upped their price objective on Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an "overweight" rating in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,017.00.

Eli Lilly and Company Stock Down 0.3 %

LLY stock traded down $2.45 during midday trading on Wednesday, hitting $825.09. 1,700,761 shares of the company's stock were exchanged, compared to its average volume of 3,423,184. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The stock has a market capitalization of $782.33 billion, a price-to-earnings ratio of 70.46, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51. The firm has a 50 day moving average price of $827.10 and a 200-day moving average price of $818.99.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.13% of the company's stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.